TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
- PMID: 31664482
- PMCID: PMC7000491
- DOI: 10.1007/s00262-019-02421-w
TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
Abstract
The TAM receptors-TYRO3, AXL, MERTK-are pleiotropically expressed receptors in both healthy and diseased tissue. A complex of the ligands Protein S (PROS1) or Growth Arrest-Specific 6 (GAS6) with apoptotic phosphatidylserine activates the TAM receptors. Hence, this receptor family is essential for the efferocytosis of apoptotic material by antigen-presenting cells. In addition, TAM receptors are expressed by virtually all cells of the tumor microenvironment. They are also potent oncogenes, frequently overexpressed in cancer and involved in survival and therapy resistance. Due to their pro-oncogenic and immune-inhibitory traits, TAM receptors have emerged as promising targets for cancer therapy. Recently, TAM receptors have been described to function as costimulatory molecules on human T cells. TAM receptors' ambivalent functions on many different cell types therefore make therapeutic targeting not straight-forward. In this review we summarize our current knowledge of the function of TAM receptors in the tumor microenvironment. We place particular focus on TAM receptors and the recently unraveled role of MERTK in activated T cells and potential consequences for anti-tumor immunity.
Keywords: CITIM 2019; Costimulation; MERTK; PROS1; T lymphocytes; TAM receptors.
Conflict of interest statement
Per thor Straten and Marlies J.W. Peeters are authors on a pending European patent 18168195.8 pertaining the use of MERTK in adoptive T cell therapy. Anne Rahbech declares no competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
